AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

10,144.00p
   
  • Change Today:
    154.00p
  • 52 Week High: 13,276.00
  • 52 Week Low: 9,501.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.30m
  • Volume: 2,741,107
  • Market Cap: £157,263m
  • RiskGrade: 123
  • Beta: 0.88

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart (13-11-2024)

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

AstraZeneca Financials

Latest F'cast
Div Yield 2.3% 0.0%
Div Cover 1.3 2.5
Op Mrgn 17.9% 29.1%
ROCE 62.6%  
Latest F'cast
P/E 33.6 16.6
PEG 0.4 0.2
Pr/Revenue 4.4 3.0
Pr/Book 5.1  
Latest F'cast
Revenue 3.3% -10.0%
PBT 175.8% 74.1%
EPS 81.1% 105.7%
DPS n/a -34.5%

AstraZeneca Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-19 24,384.00 1,548.00 103.00¢ 93.7 n/a -39% 280.00¢ 2.9%
31-Dec-20 26,617.00 3,916.00 244.00¢ 38.1 0.3 +137% 280.00¢ 3.0%
31-Dec-21 37,417.00 (265.00) 8.00¢ 1,376.8 n/a -97% 287.00¢ 2.6%
31-Dec-22 44,351.00 2,501.00 212.00¢ 67.2 0.0 +2,550% 290.00¢ 2.0%
31-Dec-23 45,811.00 6,899.00 384.00¢ 35.0 0.4 +81% 290.00¢ 2.2%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-24 52,341.38 15,247.66 611.70p 16.6 0.2 +106% 241.14p 0.0%
31-Dec-25 56,521.37 17,593.89 703.73p 14.4 1.0 +15% 253.05p 0.0%
31-Dec-26 59,934.79 19,995.96 801.15p 12.7 0.9 +14% 265.88p 0.0%

Copyright © 2024 FactSet Research Systems Inc. All rights reserved.

AstraZeneca Company Announcements

Director/PDMR Shareholding 13-Nov-2024 16:00 RNS
AstraZeneca invests $3.5 billion in US 12-Nov-2024 07:10 RNS
KOMET Phase III trial met primary endpoint 12-Nov-2024 07:05 RNS

AstraZeneca ShareCast News

London close: Stocks sink as UK jobless rate rises 12-Nov-2024 ShareCast
AstraZeneca upgrades full-year guidance amid str... 12-Nov-2024 ShareCast
AstraZeneca "excited" by positive results in Tez... 08-Nov-2024 ShareCast

AstraZeneca Top Newspaper Links

AstraZeneca boss says staff in China breached ru... 13-Nov-2024 Times
AstraZeneca raises forecasts amid investigations... 12-Nov-2024 Times
Fighting Frenchman shows us how as he ensures As... 30-Dec-2014 Daily Mail

Latest AstraZeneca Director Deals

Traded Action Notifier PriceAmountValue
11-Nov-24 Buy Philip A J Broadley 10,169.91p 980 £99,665.11
13-Sep-24 Buy Michel Demare 117.93p 2,000 £2,358.55

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 10,144.00p
Change Today 154.00p
% Change 1.54 %
52 Week High 13,276.00
52 Week Low 9,501.00
Volume 2,741,107
Shares Issued 1,550.30m
Market Cap £157,263m
Beta 0.88
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
88.81% below the market average88.81% below the market average88.81% below the market average88.81% below the market average88.81% below the market average
84% below the sector average84% below the sector average84% below the sector average84% below the sector average84% below the sector average
Price Trend
25.8% below the market average25.8% below the market average25.8% below the market average25.8% below the market average25.8% below the market average
40.00% above the sector average40.00% above the sector average40.00% above the sector average40.00% above the sector average40.00% above the sector average
Income
80.32% below the market average80.32% below the market average80.32% below the market average80.32% below the market average80.32% below the market average
42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average
Growth
88.47% above the market average88.47% above the market average88.47% above the market average88.47% above the market average88.47% above the market average
94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average

What The Brokers Say

Strong Buy 9
Buy 15
Neutral 5
Sell 0
Strong Sell 1
Total 30
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  1st Interim 2nd Interim
Ex-Div 08-Aug-24 22-Feb-24
Paid 09-Sep-24 25-Mar-24
Amount 100.00¢ 197.00¢

Trades for 13-Nov-2024

Time Volume / Share Price
18:34 1,957 @ 10,104.01p
17:07 1,593 @ 10,144.00p
17:07 73 @ 10,144.00p
17:07 243 @ 10,144.00p
17:07 861 @ 10,144.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page